BlossomHill Therapeutics, Inc. BLSM
16.12 USD +1.88 (+13.20%)
At closeNov 11, 2026, 4:00 PM EST
16.12 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
14.48 Day range 16.19
11.02 52-week range 27.99
- YTD
- +0.75%
- 1 year
- +0.75%
- Market cap
- 512.37M
- EPS (ttm)
- -4.76
- YTD return
- +0.75%
- 1-year return
- +0.75%
- Volume
- 203.68K
- Avg volume
- 197.07K
- Open
- 14.48
- Previous close
- 14.24
- Day's range
- 14.48 – 16.19
- 52-week range
- 11.02 – 27.99
5D +1.64 (+13.02%)
Financials — quick view
BLSM Revenue — quarterly 0
BLSM Net income — quarterly -23.76M
BLSM EPS — quarterly -8.75
News
BlossomHill Therapeutics Announces Alignment With FDA On 50mg Twice Daily As Recommended Phase 2 Dose For BH-30643 
BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC 
BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting 
BlossomHill Therapeutics Collaborates With Foundation Medicine To Develop Companion Diagnostic Assay For EGFR C797S Resistance Mutation 
BlossomHill Therapeutics Presents Preclinical Data On BH-501284 At AACR Conference On Pancreatic Cancer; Targets IND Filing In Q1 2027 
Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40 - Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40
Earnings Scheduled For September 18, 2026 
BlossomHill Therapeutics Q2 EPS $(8.75) 
BlossomHill Therapeutics Announces Updated Data From Ongoing Phase 1/2 SOLARA Trial Of BH-30643 In NSCLC Patients With Secondary EGFR Resistance Mutations Such As EGFR C797S
Your note
Sign in to keep a note on BLSM — it syncs with the Stock Master app.